Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 6/20 | 0.60 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.58 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.52 |
| ▸ | PRKD3 known ✓ | O94806 | 1/20 | 0.52 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.52 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.52 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.52 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.52 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.52 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.52 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.52 |
| ▸ | FGFR3 known ✓ | P22607 | 1/20 | 0.52 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.52 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.52 |
| ▸ | FLT3 known ✓ | P36888 | 1/20 | 0.52 |
| ▸ | PRKCZ known ✓ | Q05513 | 1/20 | 0.52 |
| ▸ | ITK known ✓ | Q08881 | 1/20 | 0.52 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.52 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 0.52 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30628442 | 1.00 | DHODH (0.68) | DHODHKMOPRSS1PRSS2PRSS3 | |
| SCHEMBL29788172 | 0.98 | DHODH (0.70) | DHODHKMOPRSS1PRSS2PRSS3 | |
| SCHEMBL43553 | 0.98 | DHODH (0.70) | DHODHKMOPRSS1PRSS2PRSS3 | |
| Bromide SCHEMBL30159854 | 0.96 | DHODH (0.68) | DHODHKMOPRSS1PRSS2PRSS3 | |
| Hydrogen Sulfide SCHEMBL27914334 | 0.96 | DHODH (0.68) | DHODHKMOPRSS1PRSS2PRSS3 | |
| SCHEMBL29941476 | 0.96 | DHODH (0.68) | DHODHKMOPRSS1PRSS2PRSS3 | |
| SCHEMBL6999225 | 0.94 | DHODH (0.63) | DHODHKMOPRSS1PRSS2PRSS3 | |
| SCHEMBL31422694 | 0.91 | PARP1 (0.64) | DHODHKMOPRSS1PRSS2PRSS3 | |
| SCHEMBL2431097 | 0.91 | PARP1 (0.64) | DHODHKMOPRSS1PRSS2PRSS3 | |
| Phosphoric Acid SCHEMBL19384990 | 0.90 | DHODH (0.62) | DHODHKMOPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017163258-A1 | PROCESS FOR THE PREPARATION OF N-[6-(CIS-2,6-DIMETHYLMORPHOLIN-4-YL)PYRIDINE-3-YL]-2- METHYL-4'-(TRIFIUOROMETHOXY) [1,1' -BIPHENYI]-3-CARBOXAMIDE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-09-28 | — | — | WO | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-13 | — | — | US | disclosed |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-09 | — | — | US | disclosed |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-02 | — | — | US | disclosed |
| EP-4096661-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS | Kamari Pharma Ltd. (IL) | 2022-12-07 | — | — | EP | disclosed |
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-20200407390-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | FIMBRION THERAPEUTICS INC (US) | 2020-12-31 | — | — | US | disclosed |
| WO-2017163258-A1 | PROCESS FOR THE PREPARATION OF N-[6-(CIS-2,6-DIMETHYLMORPHOLIN-4-YL)PYRIDINE-3-YL]-2- METHYL-4'-(TRIFIUOROMETHOXY) [1,1' -BIPHENYI]-3-CARBOXAMIDE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-09-28 | — | — | WO | disclosed |
| EP-3057962-A1 | HYDROCHLORIDE SALT FORM FOR EZH2 INHIBITION | Epizyme, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015057859-A1 | HYDROCHLORIDE SALT FORM FOR EZH2 INHIBITION | Epizyme, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| CN-103842332-A | Cyclopropaneamine compound | TAKAEDA CHEMICAL IND LTD | 2014-06-04 | — | — | CN | disclosed |
| WO-2014020351-A1 | RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2014-02-06 | — | — | WO | disclosed |
| EP-2054383-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236106-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | PARP1 134/4885HDAC8 1582/4885ROCK2 3506/4885 |
| US-20200407390-A1 | MANNOSE-DERIVED ANTAGONISTS OF FIMH USEFUL FOR TREATING DISEASE | MAN2B2, MAN2A1, MANBA | PARP1 1886/4885HDAC8 2148/4885ROCK2 2599/4885 |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | PARP1 134/4885HDAC8 1582/4885ROCK2 3506/4885 |
| US-20230030720-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | PARP1 134/4885HDAC8 1582/4885ROCK2 3506/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | PARP1 351/4885HDAC8 361/4885ROCK2 2197/4885 |
| US-20230074669-A1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | MLLT1, MEN1, MLLT3 | PARP1 134/4885HDAC8 1582/4885ROCK2 3506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.